Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556186 | 1.00 | VCAM1 (0.58) | VCAM1ATMTDP1HPGDALDH1A1 | |
| SCHEMBL31493 | 0.87 | VCAM1 (0.62) | VCAM1HPGDALDH1A1NPSR1PKM | |
| SCHEMBL29564693 | 0.87 | VCAM1 (0.62) | VCAM1HPGDALDH1A1NPSR1PKM | |
| SCHEMBL19058470 | 0.87 | CA1 (0.49) | VCAM1ATMTDP1HPGDALDH1A1 | |
| SCHEMBL13676425 | 0.85 | CA1 (0.47) | VCAM1ATMTDP1HPGDALDH1A1 | |
| SCHEMBL5734347 | 0.85 | VCAM1 (0.68) | VCAM1HPGDALDH1A1NPSR1PKM | |
| SCHEMBL29966142 | 0.83 | ATM (0.47) | VCAM1ATMTDP1HPGDALDH1A1 | |
| SCHEMBL30663390 | 0.83 | CTSK (0.48) | VCAM1ATMTDP1ALDH1A1NPSR1 | |
| SCHEMBL357203 | 0.83 | ATM (0.47) | VCAM1ATMTDP1HPGDALDH1A1 | |
| SCHEMBL692577 | 0.83 | KMT2A (0.60) | ATMTDP1ALDH1A1PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-122070134-A | Use of PRMT5 inhibitors in the treatment of tumors or cancers | 上海湃隆生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4732837-A2 | NOVEL PRMT5 INHIBITORS | Amgen Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4263545-B1 | PRMT5 INHIBITORS | AMGEN INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4384268-B1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT LTD (IN) | 2026-03-18 | — | — | EP | disclosed |
| WO-2003024921-A1 | ALKYL UREA RETINOID AGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
| US-6313302-B2 | OPIOID KAPPA RECEPTOR ANTAGONISTS; SIDE EFFECT REDUCTION; ANALGESICS, ANTIINFLAMMATORY AGENTS, ANESTHETICS, AND NEUROPROTECTANTS | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303602-B1 | USEFUL AS ANALGESIC, ANESTHETIC, ANTI-INFLAMMATORY OR NEUROPROTECTIVE AGENT, OR FOR THERAPY OF ARTHRITIS, STROKE OF FUNCTIONAL BOWEL DISEASE | PFIZER INC. | 2001-10-16 | — | — | US | disclosed |
| US-20010014683-A1 | Analgesics; side effect reduction | ITO FUMITAKA (JP) | 2001-08-16 | — | — | US | disclosed |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | ITO FUMITAKA (JP) | 2001-07-19 | — | — | US | disclosed |
| CN-1237962-A | Pyrrolidinyl and pyrrolinyl ethylamine compounds as K agonists | PFIZER (US) | 1999-12-08 | — | — | CN | disclosed |
| EP-0747347-B1 | RAR-gamma-specific retinobenzoic acid derivatives | BRISTOL MYERS SQUIBB CO (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5760084-A | TREATING DERMATOLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5624957-A | RETINOID ACTIVE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0747347-A1 | RARy-specific retinobenzoic acid derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138990-A1 | TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF | CD38, BCL9, BCL6B | VCAM1 292/4885ATM 3286/4885TDP1 1618/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | VCAM1 2040/4885ATM 3566/4885TDP1 3936/4885 |
| US-20260125380-A1 | PRMT5 INHIBITORS AND METHODS OF USE | PRMT1, PRMT5, PRMT6 | VCAM1 3977/4885ATM 1274/4885TDP1 808/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | VCAM1 1878/4885ATM 2365/4885TDP1 4430/4885 |
| US-20010014683-A1 | Analgesics; side effect reduction | OPRL1, OPRK1, OPRD1 | VCAM1 3681/4885ATM 4822/4885TDP1 2897/4885 |
| US-20010008890-A1 | Useful as analgesic, anesthetic, antiinflammatory or neuroprotective agents and in treatment of arthritis, stroke, bowel disease | OPRL1, NAP1L1, OPRK1 | VCAM1 849/4885ATM 4812/4885TDP1 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.